Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Circulation

• Publication date

  2000-12-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.102.23.2836PMID 11104741
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of methysergide and its metabolite methylergometrine in man

  2004cited by this paper
• Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium

  2004cited by this paper
• Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days

  2004cited by this paper
• Appetite suppressants and valvular heart disease.

  2002influential reference
• Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.

  2000cited by this paper
• 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.

  2000cited by this paper
• Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.

  2000cited by this paper
• Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications

  2000cited by this paper
• Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

  2000cited by this paper
• Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.

  1999cited by this paper
• Synergistic interactions between Fenfluramine and Phentermine

  1999cited by this paper
• Aminorex to fen/phen: an epidemic foretold.

  1999cited by this paper
• Aminorex to Fen/Phen: an epidemic foretold.

  1999cited by this paper
• Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells

  1999cited by this paper
• Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5‐HT1B and 5‐HT1D receptors expressed in various mammalian cell lines

  1998cited by this paper
• Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication

  1998cited by this paper
• An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.

  1998influential reference
• Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades.

  1998cited by this paper
• Appetite suppressants and valvular heart disease.

  1998cited by this paper
• The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

  1998cited by this paper
• 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function.

  1998cited by this paper
• A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

  1998cited by this paper
• Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients

  1998cited by this paper
• Valvular heart disease associated with fenfluramine-phentermine.

  1997cited by this paper
• High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model.

  1997cited by this paper
• Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors.

  1997cited by this paper
• Valvular heart disease associated with fenfluramine-phentermine.

  1997influential reference
• Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor

  1996cited by this paper
• Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature.

  1996cited by this paper
• Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.

  1995cited by this paper
• International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

  1994cited by this paper
• Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats.

  1993cited by this paper
• Monoamine Oxidase Inhibitors Phenelzine and Brofaromine Increase Plasma Serotonin and Decrease 5‐Hydroxyindoleacetic Acid in Patients with Major Depression: Relationship to Clinical Improvement

  1992cited by this paper
• Serotonin stimulates DNA synthesis in fibroblasts acting through 5–HT1B receptors coupled to a Gi-protein

  1988cited by this paper
• Cardiac murmurs and endocardial fibrosis associated with methysergide therapy.

  1974cited by this paper
• Complications of methysergide therapy: retroperitoneal fibrosis, mitral regurgitation, edema, and hemolytic anemia.

  1970cited by this paper

• Tailoring cariprazine for dual disorders via secondary pharmacophore optimization.

  2026cites this paper
• Pharmacotherapy for obesity management-Emphasizing the role of GLP-1 receptor agonist-based therapeutics.

  2026cites this paper
• Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors

  2026cites this paper
• Is poor dose selection undermining the translational validity of antidepressant research involving animal models?

  2025cites this paper
• Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.

  2025cites this paper
• Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease

  2025cites this paper
• Endothelial Serotonin Receptor 1B Acts as a Mechanosensor to Drive Atherosclerosis

  2025cites this paper
• A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA).

  2025cites this paper
• Metabolism of m-CPP, trazodone, nefazodone, and etoperidone: clinical and forensic aspects

  2025influential citation
• Receptor interaction profiles of 4-alkoxy-2,6-dimethoxyphenethylamines (Ψ derivatives) and related amphetamines

  2025cites this paper
• Long‐term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome

  2025cites this paper
• Diazepine Agonists of the 5‑HT2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)

  2025cites this paper
• Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice

  2025cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2025.3

  2025cites this paper
• From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications.

  2025cites this paper
• Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Mechanisms of constitutive and agonist-induced 5-HT2B internalization, persistent endosomal signaling and paradoxical regulation of agonist pharmacology.

  2025cites this paper
• Comprehensive Analysis of Clinically Discontinued Compounds Using an In Vitro Secondary Pharmacology Panel to Predict Potential Safety Risks during Drug Development.

  2025cites this paper
• Efficacy of Low-Dose Fenfluramine on Adult Patients With Lennox-Gastaut Syndrome

  2025cites this paper
• Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database

  2025cites this paper
• Non-clinical cardiovascular safety testing: Current status, gaps and emerging trends.

  2025cites this paper
• Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.

  2025cites this paper
• Cardiovascular effects and safety of classic psychedelics

  2025cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2025.1

  2025cites this paper
• Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds

  2025cites this paper
• Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited.

  2024cites this paper
• Bioisosteric analogs of MDMA: Improving the pharmacological profile?

  2024cites this paper
• Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine

  2024cites this paper
• Cardiac Surgery and Transcatheter Intervention for Valvular Heart Disease in Carcinoid Syndrome: Risk Factors, Outcomes, and Evolving Therapeutic Strategies

  2024cites this paper
• Resolution of Fenfluramine-associated pulmonary arterial hypertension in Lennox-Gastaut syndrome: A case report and literature review

  2024cites this paper
• [18F]RS-127445 radiosynthesis and evaluation as a 5-HT2B receptor PET radiotracer in rat brain.

  2024cites this paper
• Bioisosteric analogs of MDMA with improved pharmacological profile

  2024cites this paper
• Making Sense Of Psychedelics In The CNS.

  2024cites this paper
• Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins

  2024influential citation
• The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

  2023cites this paper
• Benfluorex metabolism complemented by electrochemistry-mass spectrometry.

  2023cites this paper
• Drug-induced cardiac toxicity and adverse drug reactions, a narrative review.

  2023cites this paper
• Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder?

  2023cites this paper
• The Zebrafish for Preclinical Psilocybin Research.

  2023cites this paper
• Development of a Peripherally Restricted 5-HT2B Partial Agonist for Treatment of Pulmonary Arterial Hypertension

  2023cites this paper
• 5-Hydroxytryptamine receptors in GtoPdb v.2023.1

  2023cites this paper
• Metabolic signatures in post-myocardial infarction heart failure, including insights into prediction, intervention, and prognosis.

  2023cites this paper
• Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic approach towards drug resistant epilepsy

  2023influential citation
• Activity Models of Key GPCR Families in the Central Nervous System: A Tool for Many Purposes

  2023cites this paper
• 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.

  2023cites this paper
• Amisulpride as a potential disease‐modifying drug in the treatment of tauopathies

  2023cites this paper
• Designing the 5HT2BR structure and its modulation as a therapeutic target for repurposing approach in drug-resistant epilepsy.

  2023cites this paper
• Identification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput Screen

  2023cites this paper
• 5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators

  2023cites this paper
• G protein coupled receptors as targets for transformative neuropsychiatric therapeutics.

  2023cites this paper
• Psychedelics: preclinical insights provide directions for future research

  2023cites this paper
• Targeting serotonin receptor 2B inhibits TGFβ induced differentiation of human vascular smooth muscle cells.

  2023cites this paper
• Psychedelics as Transformative Therapeutics.

  2023cites this paper
• Binding and functional structure-activity similarities of 4-substituted 2,5-dimethoxyphenyl isopropylamine analogues at 5-HT2A and 5-HT2B serotonin receptors

  2023cites this paper
• Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation

  2023cites this paper
• Fenfluramine: a plethora of mechanisms?

  2023cites this paper
• Dopamine D3/D2 Receptor Ligands Based on Cariprazine for the Treatment of Psychostimulant Use Disorders That May Be Dual Diagnosed with Affective Disorders.

  2023cites this paper
• Psilocybin history, action and reaction: A narrative clinical review

  2023cites this paper
• Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder?

  2023cites this paper
• Serotonin-releasing agents with reduced off-target effects

  2022cites this paper
• Multi-target-based polypharmacology prediction (mTPP): An approach using virtual screening and machine learning for multi-target drug discovery.

  2022cites this paper
• Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

  2022cites this paper
• Sonochemical synthesis and biological evaluation of isoquinolin-1(2H)-one/isoindolin-1-one derivatives: Discovery of a positive ago-allosteric modulator (PAAM) of 5HT2CR.

  2022cites this paper
• First quantitative dosages: Strong correlations between non-5-HT2Rs serotonin receptors on normal human heart valves

  2022cites this paper
• Docking a bespoke ultra-large tetrahydropyridine library identifies 5-HT2A receptor agonists conferring new biology

  2022cites this paper
• Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction.

  2022cites this paper
• Hedinger Syndrome: A Rare Cardiac Manifestation of Carcinoid Syndrome

  2022cites this paper
• Post-Partum Depression Lactating Rat Model for Evaluating Ketamine’s Safety as a Pharmacotherapeutic Treatment: Roles in Cardiac and Urinary Function

  2022cites this paper
• Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.

  2022cites this paper
• Discovery of Highly Potent Serotonin 5-HT2 Receptor Agonists Inspired by Heteroyohimbine Natural Products.

  2022cites this paper
• Pharmacological characterization of 3,4-methylenedioxamphetamine (MDA) analogs and two amphetamine-based compounds: N,α-DEPEA and DPIA.

  2022cites this paper
• Carcinoid heart disease.

  2022cites this paper
• The promises and perils of psychedelic pharmacology for psychiatry

  2022cites this paper
• The Relationship Between Long-Term Low-Dose Use of Cabergoline and Heart Valve Dysfunction in Pituitary Adenomas: A Retrospective Observational Study

  2022cites this paper
• Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments.

  2022cites this paper
• Serotonin receptors in epilepsy: Novel treatment targets?

  2022cites this paper
• Receptor Interaction Profiles of 4-Alkoxy-3,5-Dimethoxy-Phenethylamines (Mescaline Derivatives) and Related Amphetamines

  2022cites this paper
• What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?

  2022cites this paper
• Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo.

  2022cites this paper
• Cardiac valvular surgery and history of anorectic drug intake: A retrospective study of a large population of benfluorex-exposed patients.

  2022cites this paper
• Therapeutic drug monitoring of fenfluramine in clinical practice: Pharmacokinetic variability and impact of concomitant antiseizure medications

  2022influential citation
• Amberlyst-15 catalysed synthesis of novel indole derivatives under ultrasound irradiation: Their evaluation as serotonin 5-HT2C receptor agonists.

  2021cites this paper
• A narrative synthesis of research with 5-MeO-DMT

  2021cites this paper
• Benfluorex, Friends or Foe? The Effects of Benfluorex on Oxidative Status in the Brain During Experimental Diabetes

  2021cites this paper
• Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

  2021cites this paper
• Safety and toxicology

  2021cites this paper
• Key Characteristics of Cardiovascular Toxicants

  2021cites this paper
• The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative

  2021cites this paper
• Can preclinical drug development help to predict adverse events in clinical trials?

  2021cites this paper
• Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects in Open Field, Prepulse Inhibition, and Cognition Models

  2021cites this paper
• Quantitative prediction model for affinity of drug–target interactions based on molecular vibrations and overall system of ligand-receptor

  2021cites this paper
• Psychedelic‐inspired approaches for treating neurodegenerative disorders

  2021cites this paper
• The roles of serotonin in cell adhesion and migration, and cytoskeletal remodeling

  2021cites this paper
• 5-HT2B Receptor on Macrophages: What for?

  2021cites this paper
• 5-HT2B Receptor in Cardiopulmonary Disease

  2021cites this paper
• Drugs of Abuse Affecting 5-HT2B Receptors

  2021cites this paper
• Dissecting Calcific Aortic Valve Disease—The Role, Etiology, and Drivers of Valvular Fibrosis

  2021cites this paper
• The Discovery of 5-HT2B Receptor Pharmacology Through the Understanding of Drug-Induced Valvulopathy

  2021cites this paper
• Carcinoid Heart Disease: a Review

  2021cites this paper
• Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat

  2021cites this paper